At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jan 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 06 Dec 2000 Profile reviewed but no significant changes made
- 09 Jul 1998 Profile reviewed